Research & Development  

Scientific Overview

Scientific Presentations

Scientists 


Clinical Studies

Clinical Trial Participation

Clinical Trial Sites


Pre-Clinical Research
Product Pipeline

Scientific Reports

   
FGF-1141: Treatment Applications  
 

CVBT believes – and is studying whether – FGF-1141 can be applied to multiple tissues in the body that become injured due to a decreased blood flow. This injury, known as tissue ischemia, is most often caused by the blockage of arteries supplying blood to the tissue.

CVBT’s current development efforts for FGF-1141 are grouped by the type of tissue that is proposed for treatment. Click on the image below to learn more about how FGF-1141 applies to various areas of the body.

body

 


 

 

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.

 

11/13/2008
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate


9/9/2008
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial


7/1/2008
Dutton Associates Announces Investment Opinion: CardioVascular BioTherapeutics Maintained At Neutral Rating By Dutton Associates


6/10/2008
CVBT Inks Third Clinical Development Agreement